Mesenchymal stem/progenitor cells (MSC/MPC) from a variety of tissue sources (bone marrow, adipose tissue, fat pads, synovial membranes, synovial fluid, skin, muscle and periosteal tissue) have been widely applied for tissue engineering applications to generate replacements for injured or degenerated tissues. Alternatively, they have also been injected as free cells in an attempt to facilitate in vivo repair. Nearly all studies reported have used mixed cell populations of MSC/MPC, usually defined by cell surface phenotypes and/or functional ability to differentiate towards multiple cell lineages. Using more detailed cell surface phenotyping and limiting dilution approaches to isolate individual MSC/MPC clones have indicated that such mixed cell populations are very heterogeneous. In addition subsets of cells from different sources may have epigenetic modifications. While it is clear that MSC/MPC cells exhibit heterogeneity, the question of why this is the case has not been well addressed. This review will address some of these issues, as well as provide some insights into the implications when using such diverse cells for tissue engineering applications.
dressed in detail. Possibilities include age, sex, genetics, environmental factors (inflammation, nutrition, stress), replicative senescense [19] , and potentially epigenetics. The latter factor has also been addressed by Noer et al. [20] and Schellenberg et al. [19] , and shown to also vary within adipose-derived cells, and between bone marrow and adipose-derived cells, respectively. From the above discussion, it is clear that heterogeneity exists in and between MSC/MPC populations derived from different tissue sources. Therefore, the critical question is not whether it exists, but why it exists! This can vary between species as for some species one has to use adherence to culture dishes and antibodies that cross-react with specific surface markers (e.g. CD90, CD105, CD73, CD39, etc). The, MSC/MPC from various tissues are usually phenotyped by being positive for some markers and negative for others. Therefore, the current battery of markers may define the general category of MSC/MPC, but this covers multiple subsets. Evidence for this concept comes from the Gullo and DeBari [5] studies cited above where they identified a subset of MSC using CD39+CD73+ cells to define a subpopulation exhibiting a specific set of features. It is likely that as the MSC/MPC field progresses, using both cell surface phenotyping and lineage-specific functional assays, better definition of MSC/MPC subsets will evolve. While the above will effectively recapitulate what was done for the field of hematopoietic stem cells decades ago, it will still not address the reasons for the within and between tissue heterogeneity. Perhaps we need to assess individual cell secretosomes to also assess the secretion of growth factors/regulators/ modifiers ("nurse" cells) as this may be a function that assists other cells better become cartilage, bone, heart tissue, muscle, etc in vivo rather than artificially in vitro. Likely there are many other functions one could envision for such cells other than regeneration/repair of damaged tissues (normal turnover vs overt injury vs subclinical repair). One approach will be to assess in vivo functioning of isolated clones vs. mixed populations in a variety of circumstances/situations. Another possibility to explain the heterogeneity of MSC populations is that it is reflective of a "mixing" of endogenously produced MSC in a specific tissue (e.g. fat pad of the knee or the synovium of the knee with cells that either circulate from other sites of production (e.g. bone marrow) and localize in the synovial fluid of the knee either through attraction via trophic factors, or via a stochastic process of localization and re-location. MSC/MPC produced in different locations may exhibit tissue-specific clonal "signatures" due to the microenvironment they are produced in (e.g. unique epigenetic signatures; [20] ). Given this scenario, not only are the different microenvironments (e.g. bone marrow, skin, synovium, synovial fluid) different biologically, but also mechanically. For instance, synovial fluid contains high levels of hyaluronans and other lubricating molecules which can also have biological activities (e.g. hyaluronans and CD44 or RHAMM; [21] [22] ). Thus, it may be naïve to conclude that MSC/MPC developing in the bone marrow, which is a unique environment biologically, will function optimally in the mechanical and biological environment of the knee. If we add in the genetic diversity of individuals, as well as their varied MSC "history", then one has a number of factors which could account for some of the observed diversity and heterogeneity.
Potential Explanations for the

The Lineages
In some respects, such a mixing of cells is analogous to what has been observed at delayed hypersensitivity sites, were <1 in 100 T-lymphocytes at the site are antigen-specific, and therefore, many cells localize to the site not because of the antigenic stimuli, but because of the response to the antigenic stimuli with the release of trophic factors that are not antigen-specific. However, the concept of "clonal signatures" for individual clones of MSC/MPC is somewhat attractive, and one that should be pursued going forward using both cell surface pheno-typing and functional assessments. Certainly such signatures may not be the same as those for T-and B-lymphocytes (arising via recombination in a clonal manner), but there may be a parallel system for identifying unique subsets of MSC/MPC.
An important set of questions remain, and they are: Is the heterogeneity "planned" or random, and is the diversity an intrinsic strength of the system, or are we over interpreting its significance? The answers to such questions are important from the perspective of understanding the impact and regulation of MSC/MPC, but also from the perspective of using such cells for endogenous and exogenous tissue engineering applications.
Finally, one has to acknowledge that some of the heterogeneity may be an artifactual result of culturing MSC/MPC in vitro in artificial conditions (e.g. fetal bovine serum, non-optimized culture media, in plastic dishes, etc). Clearly, these are non-normal conditions for cells from unique biological and mechanical environments that likely can "skew" the outcomes of proliferation and differentiation assays. Relevant to this point is a recent set of studies by Dry et al. [23] , indicating that the calcium concentration of synovial fluid is much higher than what is found in many common tissue culture media, and supplementing the media with additional calcium salts leads to an overt acceleration in proliferation rates. Therefore, the cells are cultured in media of convenience, rather than the most optimal conditions which mimic the in vivo environments. This concept of cells in vitro being conditioned by the microenvironment has also been discussed by Gregory et al. [24] .
Irrespective of MSC/MPC Heterogeneity, Undifferentiated MSC/MPC Used for Generating an in Vitro Tissue Engineered Construct (TEC), Can Still Lead to Effective in Vivo Cartilage Repair
While the above discussion has raised issues regarding MSC/MPC cell heterogeneity, and the potential basis for such heterogeneity, it is clear that generating TEC in vitro with undifferentiated MSC/MPC leads to constructs that can adhere in vivo to defects in articular hyaline cartilage and adapt to become an effective repair tissue out to 1 year post-implantation in either adolescent or adult porcine models (discussed in [25] [26] [27] ). Furthermore, osteo-TEC constructs also become integrated in both porcine and rabbit models [28] [29] . Thus, such MSC/MPC constructs are able to differentiate in vivo in the microenvironment (biology and biomechanics) of the knee to become a close to normal looking and functioning cartilage. However, it is not perfect as the extreme surface layer (lamina splendans) is not normal [30] . However, one current limitation is that it has not been clearly shown that the cells populating the implant are the same ones that were in the original TEC. It will be important to clarify this point in the future, as well as determine whether TEC generated from differentiated mixed populations or TEC generated with clonal MSC/MPC are as effective as the above discussed TEC for long term cartilage, meniscal [31] , or bone repair (discussed in [32] ). In addition, other laboratories have reported that injection of MSC derived from synovium into rabbit knees can lead to significant repair of massive meniscal defects over a 6 month period post-injection [33] . Some (a small percentage) of the injected cells did home to the site of the damage and were detectable for 14 days [33] , so even if only a small percentage of the isolated cells are effective, it may be sufficient. Similarly, other authors have used this approach to repair meniscal defects in other models [34] . However, if that small population could be identified and isolated, perhaps the long term outcomes could be improved yielding an engineered tissue which optimally adapts to the meniscal microenvironment.
Implication of MSC/MPC Heterogeneity for Tissue Engineering Applications
As heterogeneity in MSC populations/subpopulations may arise from genetic, epigenetic, localization-relocalization, site history, and likely sex/gender factors, this variability may be of concern for those applying such cell populations to generate tissue engineered replacement tissues. This is likely a concern for both autologous and allogeneic applications, but likely of more concern for allogeneic applications. Thus, using mixed populations with intrinsic variation with regard to the subpopulations present may lead to varied outcomes that may not be predictable. Therefore, using very well characterized clonal populations as the "starting material" for generating an engineered construct may be the preferred approach to minimize variation and risk.
Use of such clonal populations may also mitigate potential risk of unwanted complications associated with the use of mixed populations. While there is the general perception that MSC/MPC do not pose any safety risks, it is still not clear that all MSC that exhibit the ability to proliferate extensively, have epigenetic modifications that may influence gene regulation and responsiveness to stimuli, and retain the ability to differentiate along several lineages, do not pose some risk until proven otherwise. Given the emerging literature regarding the role of tissue-specific stem cells in various cancers [35] [36] [37] ; and many others), proof of no risk in this regard is essential and using well defined clonal populations may mitigate some of that risk.
Summary
Studies with MSC/MPC from multiple sources indicate that cells rising in or localized to specific environments are very heterogeneous and apparently influenced by their microenvironment. While there are likely several clues as to how such heterogeneity arises and is maintained, for what purpose is still unclear and needs further investigation. Such heterogeneity has many implications for those interested in using mixed populations for tissue engineering applications, but it remains to be better understood whether mixed populations or individual clones of MSC/MPC are the best starting cells for tissue engineering applications for the long term repair/regeneration of damaged or injured tissues. Finally, while it is assumed in some quarters that MSC/MPC pose no safety risk, many clinical trials are likely warranted to confirm there is no risk, or that risk can be mitigated by using well characterized clonal cells.
